Decentralized Trials Position Clinical Ink as a one-stop partner for sponsors and CROs seeking patient-centric, data-rich decentralized trials, leveraging Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers to improve data quality and patient engagement.

Kaitality Opportunity Capitalize on the Kaitality launch to cross-sell into GLP-1 and metabolic disease programs, offering integrated adherence support and objective measures of weight and activity to enhance outcomes data.

Digital Artefacts Leverage the Digital Artefacts acquisition to expand digital endpoints and remote assessment capabilities, enabling deeper analytics and faster study timelines for sponsors seeking modern, endpoint-driven trials.

EMEA Growth Leverage recent leadership in EMEA to pursue regional expansion, offering localized solutions, regulatory alignment, and data capture platforms tailored to European and nearby markets.

Strategic Partnerships Position as a preferred tech-enabled CRO-sponsor partner by highlighting a combined platform of telehealth, digital biomarkers, and advanced data capture to accelerate study startup, improve data quality, and reduce site burden.